drugset / Trial / NCT06372626
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
RandomizedParallel-groupSingle-blindTreatment
Summary
The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.
Timeline
- Start
- 2024-05-30
- Primary completion
- 2026-07
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZG005 | Unknown | 10 mg/kg | Intravenous |
| Subject | ZG005 | Unknown | 20 mg/kg | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Etoposide | Small molecule | — | Intravenous |